Contrarian Codex — Merlin Labs: C-130J CDR passed (update)

Ticker	Name	Research	View	What he said	At
MRLN	Merlin Labs	QT · SA · STK · FA	Positive	Merlin passed the C-130J Critical Design Review — the single most important near-term gate — moving the program from design to integration/testing and protecting the $105m IDIQ; price targets unchanged ($16 / $77 / $216) but probability re-weighted to ~25% bear / 50% base / 25% bull, with the true bear case still $0.	read ↗

What CDR means — design phase ends, build phase begins

The Critical Design Review is the government checkpoint where engineers audit the full system architecture — component interfaces, software design, fault handling, safety mechanisms, integration plans — and decide whether the design is mature enough to proceed into physical hardware integration and testing.
USSOCOM formally reviewed and approved the Merlin Pilot autonomy stack as it will be integrated onto the C-130J Super Hercules; CEO George confirmed it "validates the architecture we've built for safe, scalable autonomy on large aircraft."
Before CDR there was a legitimate question of whether USSOCOM would send Merlin back to the drawing board; that question is now answered — the design is sound, proceed to integration. What remains are engineering and manufacturing challenges, not architectural ones.
Programs can still fail after CDR, but the failure mode shifts: "can this work?" becomes "how well and how fast does this work?" and "will we use it at scale?"

Contract effect — task-order flow should accelerate 2H-2026 into 2027

Passing CDR protects the existing task orders under the $105m IDIQ ceiling and unlocks the next phases of work; revenue from the C-130J program should begin to accelerate in 2H-2026 and into 2027.
Q1 revenue of $1m was always going to be light — the program was in design phase; now that it has moved into integration and testing, task-order flow should pick up.
Three investor conferences in June (Jefferies Defense Tech Summit, Roth's London Conference Jun 16–18, Maxim's Defense Tech Conference Jun 25) now have CDR as a confirmed talking point rather than a pending risk, changing the tenor of every management chat with institutional capital.

TD Cowen initiates — two analysts, consensus ~$13

On June 3 — one day before the CDR announcement — TD Cowen initiated coverage with a Buy rating and an $11 price target, representing ~45% upside from the pre-announcement close.
Mart had flagged TD Cowen as the most likely next initiator in the deep dive, noting their role as co-placement agent on the $80m PIPE.
Merlin now has two sell-side analysts: Roth at Buy/$15 and TD Cowen at Buy/$11; consensus ~$13 — a good start; Mart expects those targets to move up as the program delivers.
TD Cowen's initiation correctly frames the thesis: C-130J and KC-135 contracts as the foundation, with EBITDA and free cash flow remaining negative for years — "this is not a stock you buy for next quarter's earnings."
The institutional discovery phase Mart said had not yet begun could now be underway in a meaningful way.

The short-interest setup — favourable mechanics, not a squeeze call

Short interest climbed from 3.1m shares on May 21 to 4.6m shares on June 3, with borrow rates running at 36–38%; on a stock with a thin float, 4.6m shares short represents a substantial portion of freely tradeable supply and 3× daily average volume to cover.
The 30–40%+ after-hours move on the CDR news put a notable portion of those shorts underwater; high borrow rates meant shorts were already paying a premium to hold positions before the news.
Mart explicitly declines to predict a short squeeze — flows and positioning are not visible from the outside — but notes the mechanical setup (genuine fundamental catalyst + major short interest + 37% borrow + minimal float) is "about as favourable as it gets for the long side."
April's 155% move in a single week is the precedent for what this combination can produce.

Probability re-weighting & the next catalyst

Price targets are unchanged: bear ~$16, base ~$77, bull ~$216 — all were built on the assumption Merlin would eventually clear CDR; the real bear case remains $0.
What changes is the probability weighting: from 35% bear / 45% base / 20% bull → ~25% bear / 50% base / 25% bull. "Not all-out fully-derisked bull mode yet, but a good step in the right direction."
The sequence from here: integration → ground testing → flight demonstration; the next major catalyst is first flight — when the Merlin Pilot actually flies a C-130J takeoff-to-touchdown — targeted for late 2026 (timeline is tight and defense schedules are notoriously elastic).
Q2 results in the near term should show whether CDR completion is translating into accelerated task-order flow.

3. In plain English

MRLN — Merlin Labs Positive

Think of CDR as the government's final exam on the blueprints. Before yesterday, there was a real chance the US military could have looked at Merlin's design for flying a C-130J autonomously and said "go back and redo this." They didn't — they said "the design is sound, now go build it." That's a big deal: a lot of defence startups never make it past this gate.

What it doesn't change: the price targets ($16 bear / $77 base / $216 bull) and the fact that the real downside is still $0 if execution fails. What it does change is the odds. Mart moves his probability from roughly one-in-three chance of a bad outcome down to one-in-four, and shifts more weight toward the middle and upper cases. The company still has to physically integrate the software into the aircraft, run ground tests, and then actually fly it — that's all still ahead, targeted for later this year — but those are engineering hurdles, not "does the design even work" hurdles.

The stock is already up ~60% from the $6 entry because the market is pricing in exactly this shift. Two Wall Street analysts now cover it (both Buy-rated, consensus ~$13). There are also a lot of short-sellers caught offside — over 4.6 million shares betting the stock goes down, at expensive borrow rates — which adds fuel to near-term moves. Mart isn't calling a squeeze, but he notes the setup is as favourable as it gets for people who are already long.

Analysis distilled from the Contrarian Codex written report (PDF linked above). For personal study — not investment advice. Source material © Contrarian Codex / "Mart".